Appendix A
Workshop Agenda

The Value of Genetic and Genomic Technologies


The Beckman Center of the National Academies

100 Academy

Irvine, CA


March 22, 2010


MEETING OBJECTIVE


To examine the perceived value of genetic and genomic technologies, both present and future, in clinical practice

  • How do different stakeholders define the value of genetic and genomic technologies?

  • How do stakeholders evaluate the weight of one kind of value in relation to another?

  • How do people assess relative values to make health care decisions?

  • How do these types of values relate, or not relate, to the monetary cost of the technologies?

8:00–8:15 A.M.

PUBLIC WORKSHOP BEGINS—AUDITORIUM

8:00–8:15 A.M.

Welcome and Introductory Remarks

 

Wylie Burke, Roundtable Chair and Professor and Chair of the Department of Bioethics and Humanities, University of Washington



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 57
Appendix A Workshop Agenda The Value of Genetic and Genomic Technologies The Beckman Center of the National Academies 100 Academy Irvine, CA March 22, 2010 MEETING OBJECTIVE To examine the perceived value of genetic and genomic technologies, both present and future, in clinical practice • How do different stakeholders define the value of genetic and genomic technologies? • How do stakeholders evaluate the weight of one kind of value in relation to another? • How do people assess relative values to make health care decisions? • How do these types of values relate, or not relate, to the monetary cost of the technologies? 8:00–8:15 A.M. PUBLIC WORKSHOP BEGINS—AUDITORIUM Welcome and Introductory Remarks 8:00–8:15 A.M. Wylie Burke, Roundtable Chair and Professor and Chair of the Department of Bioethics and humanities, university of Washington 

OCR for page 57
 ThE VALuE Of GENETIC AND GENOMIC TEChNOLOGIES 8:15–10:15 A.M. CORRELATION BETWEEN LyNCH SyNDROME AND COLON CANCER Case Study Presentation 8:15–8:30 A.M. Marc Williams, Director, Intermountain healthcare Clinical Genetics Institute, LDS hospital Lynch Syndrome Panelists 8:30–9:00 A.M. Mark Boguski, Associate Professor, Center for Biomedical Informatics, harvard Medical School Roy Gandolfi, Associate Medical Director, Selecthealth Don Lyman, Chief, Chronic Disease and Injury Control Division, California Department of Public health Dennis Salisbury, family Practice Physician, Rocky Mountain Clinic, Butte, MT Andrew Spiegel, CEO, Colon Cancer Alliance Panel discussion 9:00–9:45 A.M. Roundtable discussion 9:45–10:15 A.M. 10:15–10:30 A.M. BREAK 10:30–12:30 P.M. PHARMACOGENOMIC TESTING FOR WARFARIN DOSING Case Study Presentation 10:30–10:45 A.M. David Veenstra, Associate Professor, Pharmaceutical Outcomes Research and Policy Program and Institute for Public health Genetics, university of Washington Warfarin Panelists 10:45–11:15 A.M. Anna Garrett, Manager, Outpatient Clinical Pharmacy Programs, Mission hospital, Asheville, NC

OCR for page 57
 APPENDIX A Arthur Lurvey, Medical Director, Palmetto GBA Elizabeth Mansfield, Director of the Personalized Medicine Staff, Office of In Vitro Diagnostic Devices, Center for Devices and Radiological health, fDA Dennis Salisbury, family Practice Physician, Rocky Mountain Clinic, Butte, MT 11:15 A.M.–12:00 P.M. Panel discussion Roundtable discussion 12:00–12:30 P.M. 12:30–1:30 P.M. LUNCH 1:30–4:00 P.M. GENOMIC PROFILING Case Study Presentation 1:30–1:45 P.M. Bruce Blumberg, Co-Chief of Medical Genetics, Kaiser Permanente, Oakland and Institutional Director of Graduate Medical Education, Northern California Kaiser Permanente, The Permanente Medical Group Genomic Profiling Panelists 1:45–2:15 P.M. Karen Kaplan, Science Writer, Los Angeles Times Vance Vanier, CEO and President, Navigenics Janet Williams, Genetic Counselor, Intermountain healthcare, Oncology Clinics David Witt, Genetics Department, Kaiser San Jose Medical Center Steven Woolf, Professor, Departments of family Medicine, Epidemiology, and Community health, Virginia Commonwealth university Panel discussion 2:15–3:15 P.M.

OCR for page 57
0 ThE VALuE Of GENETIC AND GENOMIC TEChNOLOGIES Roundtable discussion 3:15–4:00 P.M. 4:00–5:00 P.M. SUMMARy Summary and wrap-up discussion 4:00–5:00 P.M. Bruce Blumberg, Co-Chief of Medical Genetics, Kaiser Permanente, Oakland and Institutional Director of Graduate Medical Education, Northern California Kaiser Permanente, The Permanente Medical Group Wylie Burke, Roundtable Chair and Professor and Chair of the Department of Bioethics and humanities, university of Washington Catherine A. Wicklund, Director of the Graduate Program in Genetic Counseling and Assistant Professor, Department of Obstetrics and Gynecology, Northwestern university Marc Williams, Director, Intermountain healthcare Clinical Genetics Institute, LDS hospital 5:00 P.M. ADJOURN